Across its top 6 institutional holders, AKTX's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 12/100, avg. turnover score 29/100).

Quarterly Activity

Recent Activity

+$307.3K

Total Buy Value

$0.0

Total Sell Value

New buy6

Trim0

Add0

Sold out0

Net Buyers

Net Sellers

Smart Money Convergence

AKTX does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/AKTX

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-02

2026-07-02

Akari Therapeutics held its Annual General Meeting on June 30, 2026, and shareholders voted on multiple resolutions. A notable outcome is that director James Neal was not re-elected and left the board immediately after the meeting. The board then appointed Dr. Ray Prudo to fill the Audit Committee vacancy.

View Full Filing (SEC EDGAR)

2026-06-26

AI summary pending

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

00972G405

FAQ

Who are the top institutional investors holding AKARI THERAPEUTICS PLC-ADR (AKTX)?

Major stakeholders currently include Armistice Capital, LLC ($200.4K), Cresset Asset Management, LLC ($105.9K), IFP Advisors, Inc ($932.0). Based on the latest 13F filings, there are a total of 6 tracked investment funds and institutions maintaining positions in AKTX.

What is the overall institutional sentiment toward AKTX recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $307.3K, driven by 6 managers accumulating shares while 0 reduced their exposure.

Which institutions have been selling or reducing their AKTX positions?

In the latest period, no tracked funds trimmed or exited their positions in AKTX.

Are there any notable investors adding AKTX to their portfolios?

Yes, buying activity remains notable. 6 institutions opened new positions in {ticker}, and 0 existing holders added to their shares. The total reported buy value for the quarter amounted to $307.3K.

Related Stocks

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,153

Total reported value

$2.1T

3246 13F institutions increased their position this quarter

View detail

AMZN

Amazon.com INC

Institutions Holding

5,960

Total reported value

$1.5T

3030 13F institutions increased their position this quarter

View detail

NVDA

Nvidia CORP

Institutions Holding

5,769

Total reported value

$3.0T

2744 13F institutions increased their position this quarter

View detail

Developer Access

Access AKTX's institutional ownership data programmatically:

REST API

curl https://alphasmo.com/api/v1/market/stock/AKTX

CLI

npx alphasmo stocks get AKTX

Full API & MCP documentation →